Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luxeptinib - Aptose Biosciences/CrystalGenomics

Next Previous
Drug Profile

Luxeptinib - Aptose Biosciences/CrystalGenomics

Alternative Names: CG-026806; CG-806

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CrystalGenomics
  • Developer Aptose Biosciences; CrystalGenomics
  • Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoindoles; Phenylurea compounds; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Aurora kinase inhibitors; Discoidin domain receptor 2 antagonists; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Interleukin 6 inhibitors; Lyn protein-tyrosine kinase inhibitors; NLRP3 protein inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-akt inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Preclinical Mantle-cell lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 26 Mar 2024 Aptose plans a phase II and phase III trials (Combination therapy) in 2H 2025
  • 26 Mar 2024 Luxeptinib - Aptose Biosciences/CrystalGenomics is available for licensing as of 26 Mar 2024. https://www.aptose.com/
  • 05 Apr 2023 Aptose Biosciences has patent protection for compounds including CG 806, pharmaceutical compositions comprising CG 806, and methods of their use for treating various diseases in USA and Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top